Abstract
Summary
Somatostatin analogues stop your body from making too many hormones. They can reduce the symptoms of carcinoid syndrome and may slow down tumour growth.
LPI (LP Information)' newest research report, the “Somatostatin Analogs Industry Forecast” looks at past sales and reviews total world Somatostatin Analogs sales in 2022, providing a comprehensive analysis by region and market sector of projected Somatostatin Analogs sales for 2023 through 2029. With Somatostatin Analogs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Somatostatin Analogs industry.
This Insight Report provides a comprehensive analysis of the global Somatostatin Analogs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Somatostatin Analogs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Somatostatin Analogs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Somatostatin Analogs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Somatostatin Analogs.
The global Somatostatin Analogs market size is projected to grow from US$ 4402.4 million in 2022 to US$ 6272.2 million in 2029; it is expected to grow at a CAGR of 6272.2 from 2023 to 2029.
Somatostatin is a protein made naturally in the body. It is made by: a gland in the brain (hypothalamus), the stomach, the pancreas and the bowel. Somatostatin can slow down hormone production, including many of the gut hormones, slows down the emptying of the stomach and bowel, controls the release of hormones made by the pancreas, including insulin and, slows down or stops the release of growth hormones. Rise in the research and development and launch of novel drug therapies are the factors driving the growth of somatostatin analogs over the forecast period.
This report presents a comprehensive overview, market shares, and growth opportunities of Somatostatin Analogs market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Octreotide
Lanreotide
Pasireotide
Segmentation by application
Acromegaly
Carcinoid Syndrome
Neuroendocrine Tumor
Cushing Syndrome
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
Peptron
Chiasma
Ipsen Biopharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Somatostatin Analogs market?
What factors are driving Somatostatin Analogs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Somatostatin Analogs market opportunities vary by end market size?
How does Somatostatin Analogs break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
LPI (LP Information)' newest research report, the “Somatostatin Analogs Industry Forecast” looks at past sales and reviews total world Somatostatin Analogs sales in 2022, providing a comprehensive analysis by region and market sector of projected Somatostatin Analogs sales for 2023 through 2029. With Somatostatin Analogs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Somatostatin Analogs industry.
This Insight Report provides a comprehensive analysis of the global Somatostatin Analogs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Somatostatin Analogs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Somatostatin Analogs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Somatostatin Analogs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Somatostatin Analogs.
The global Somatostatin Analogs market size is projected to grow from US$ 4402.4 million in 2022 to US$ 6272.2 million in 2029; it is expected to grow at a CAGR of 6272.2 from 2023 to 2029.
Somatostatin is a protein made naturally in the body. It is made by: a gland in the brain (hypothalamus), the stomach, the pancreas and the bowel. Somatostatin can slow down hormone production, including many of the gut hormones, slows down the emptying of the stomach and bowel, controls the release of hormones made by the pancreas, including insulin and, slows down or stops the release of growth hormones. Rise in the research and development and launch of novel drug therapies are the factors driving the growth of somatostatin analogs over the forecast period.
This report presents a comprehensive overview, market shares, and growth opportunities of Somatostatin Analogs market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Octreotide
Lanreotide
Pasireotide
Segmentation by application
Acromegaly
Carcinoid Syndrome
Neuroendocrine Tumor
Cushing Syndrome
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
Peptron
Chiasma
Ipsen Biopharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Somatostatin Analogs market?
What factors are driving Somatostatin Analogs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Somatostatin Analogs market opportunities vary by end market size?
How does Somatostatin Analogs break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Somatostatin Analogs Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Somatostatin Analogs by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Somatostatin Analogs by Country/Region, 2018, 2022 & 2029
2.2 Somatostatin Analogs Segment by Type
2.2.1 Octreotide
2.2.2 Lanreotide
2.2.3 Pasireotide
2.3 Somatostatin Analogs Sales by Type
2.3.1 Global Somatostatin Analogs Sales Market Share by Type (2018-2023)
2.3.2 Global Somatostatin Analogs Revenue and Market Share by Type (2018-2023)
2.3.3 Global Somatostatin Analogs Sale Price by Type (2018-2023)
2.4 Somatostatin Analogs Segment by Application
2.4.1 Acromegaly
2.4.2 Carcinoid Syndrome
2.4.3 Neuroendocrine Tumor
2.4.4 Cushing Syndrome
2.4.5 Others
2.5 Somatostatin Analogs Sales by Application
2.5.1 Global Somatostatin Analogs Sale Market Share by Application (2018-2023)
2.5.2 Global Somatostatin Analogs Revenue and Market Share by Application (2018-2023)
2.5.3 Global Somatostatin Analogs Sale Price by Application (2018-2023)
3 Global Somatostatin Analogs by Company
3.1 Global Somatostatin Analogs Breakdown Data by Company
3.1.1 Global Somatostatin Analogs Annual Sales by Company (2018-2023)
3.1.2 Global Somatostatin Analogs Sales Market Share by Company (2018-2023)
3.2 Global Somatostatin Analogs Annual Revenue by Company (2018-2023)
3.2.1 Global Somatostatin Analogs Revenue by Company (2018-2023)
3.2.2 Global Somatostatin Analogs Revenue Market Share by Company (2018-2023)
3.3 Global Somatostatin Analogs Sale Price by Company
3.4 Key Manufacturers Somatostatin Analogs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Somatostatin Analogs Product Location Distribution
3.4.2 Players Somatostatin Analogs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Somatostatin Analogs by Geographic Region
4.1 World Historic Somatostatin Analogs Market Size by Geographic Region (2018-2023)
4.1.1 Global Somatostatin Analogs Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Somatostatin Analogs Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Somatostatin Analogs Market Size by Country/Region (2018-2023)
4.2.1 Global Somatostatin Analogs Annual Sales by Country/Region (2018-2023)
4.2.2 Global Somatostatin Analogs Annual Revenue by Country/Region (2018-2023)
4.3 Americas Somatostatin Analogs Sales Growth
4.4 APAC Somatostatin Analogs Sales Growth
4.5 Europe Somatostatin Analogs Sales Growth
4.6 Middle East & Africa Somatostatin Analogs Sales Growth
5 Americas
5.1 Americas Somatostatin Analogs Sales by Country
5.1.1 Americas Somatostatin Analogs Sales by Country (2018-2023)
5.1.2 Americas Somatostatin Analogs Revenue by Country (2018-2023)
5.2 Americas Somatostatin Analogs Sales by Type
5.3 Americas Somatostatin Analogs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Somatostatin Analogs Sales by Region
6.1.1 APAC Somatostatin Analogs Sales by Region (2018-2023)
6.1.2 APAC Somatostatin Analogs Revenue by Region (2018-2023)
6.2 APAC Somatostatin Analogs Sales by Type
6.3 APAC Somatostatin Analogs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Somatostatin Analogs by Country
7.1.1 Europe Somatostatin Analogs Sales by Country (2018-2023)
7.1.2 Europe Somatostatin Analogs Revenue by Country (2018-2023)
7.2 Europe Somatostatin Analogs Sales by Type
7.3 Europe Somatostatin Analogs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Somatostatin Analogs by Country
8.1.1 Middle East & Africa Somatostatin Analogs Sales by Country (2018-2023)
8.1.2 Middle East & Africa Somatostatin Analogs Revenue by Country (2018-2023)
8.2 Middle East & Africa Somatostatin Analogs Sales by Type
8.3 Middle East & Africa Somatostatin Analogs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Somatostatin Analogs
10.3 Manufacturing Process Analysis of Somatostatin Analogs
10.4 Industry Chain Structure of Somatostatin Analogs
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Somatostatin Analogs Distributors
11.3 Somatostatin Analogs Customer
12 World Forecast Review for Somatostatin Analogs by Geographic Region
12.1 Global Somatostatin Analogs Market Size Forecast by Region
12.1.1 Global Somatostatin Analogs Forecast by Region (2024-2029)
12.1.2 Global Somatostatin Analogs Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Somatostatin Analogs Forecast by Type
12.7 Global Somatostatin Analogs Forecast by Application
13 Key Players Analysis
13.1 Novartis
13.1.1 Novartis Company Information
13.1.2 Novartis Somatostatin Analogs Product Portfolios and Specifications
13.1.3 Novartis Somatostatin Analogs Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Novartis Main Business Overview
13.1.5 Novartis Latest Developments
13.2 Peptron
13.2.1 Peptron Company Information
13.2.2 Peptron Somatostatin Analogs Product Portfolios and Specifications
13.2.3 Peptron Somatostatin Analogs Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Peptron Main Business Overview
13.2.5 Peptron Latest Developments
13.3 Chiasma
13.3.1 Chiasma Company Information
13.3.2 Chiasma Somatostatin Analogs Product Portfolios and Specifications
13.3.3 Chiasma Somatostatin Analogs Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Chiasma Main Business Overview
13.3.5 Chiasma Latest Developments
13.4 Ipsen Biopharmaceutical
13.4.1 Ipsen Biopharmaceutical Company Information
13.4.2 Ipsen Biopharmaceutical Somatostatin Analogs Product Portfolios and Specifications
13.4.3 Ipsen Biopharmaceutical Somatostatin Analogs Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Ipsen Biopharmaceutical Main Business Overview
13.4.5 Ipsen Biopharmaceutical Latest Developments
14 Research Findings and Conclusion